A randomized phase II study of degarelix combined with anti-androgen for prostate cancer
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2016
Price : $35 *
At a glance
- Drugs Bicalutamide (Primary) ; Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 Jun 2015 Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 May 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 20 Aug 2013 New trial record